

Michel Boutin

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/616944/publications.pdf>

Version: 2024-02-01

46
papers

1,067
citations

489802

18
h-index

466096

32
g-index

46
all docs

46
docs citations

46
times ranked

1176
citing authors

#	ARTICLE	IF	CITATIONS
1	Lysosphingolipid urine screening test using mass spectrometry for the early detection of lysosomal storage disorders. <i>Bioanalysis</i> , 2022, 14, 289-306.	0.6	1
2	Quantitation of a plasma biomarker profile for the early detection of Gaucher disease type 1 patients. <i>Bioanalysis</i> , 2022, 14, 223-240.	0.6	0
3	Metabolomic Study Using Time-of-Flight Mass Spectrometry Reveals Novel Urinary Biomarkers for Gaucher Disease Type 1. <i>Journal of Proteome Research</i> , 2022, 21, 1321-1329.	1.8	2
4	Methylmalonic acid analysis using urine filter paper samples to screen for metabolic vitamin B ₁₂ deficiency in older adults. <i>Bioanalysis</i> , 2022, 14, 615-626.	0.6	1
5	Vitamin B-12 Intake from Dairy but Not Meat Is Associated with Decreased Risk of Low Vitamin B-12 Status and Deficiency in Older Adults from Quebec, Canada. <i>Journal of Nutrition</i> , 2022, 152, 2483-2492.	1.3	8
6	Quantitation of a Urinary Profile of Biomarkers in Gaucher Disease Type 1 Patients Using Tandem Mass Spectrometry. <i>Diagnostics</i> , 2022, 12, 1414.	1.3	3
7	Lentivirus-mediated gene therapy for Fabry disease. <i>Nature Communications</i> , 2021, 12, 1178.	5.8	58
8	Neonatal Urine Screening Program in the Province of Quebec: Technological Upgrade from Thin Layer Chromatography to Tandem Mass Spectrometry. <i>International Journal of Neonatal Screening</i> , 2021, 7, 18.	1.2	4
9	Globotriaosylsphingosine (lyso-Cb3) and analogues in plasma and urine of patients with Fabry disease and correlations with long-term treatment and genotypes in a nationwide female Danish cohort. <i>Journal of Medical Genetics</i> , 2021, 58, 692-700.	1.5	13
10	The clinical utility of total concentration of urinary globotriaosylsphingosine plus its analogues in the diagnosis of Fabry disease. <i>Clinica Chimica Acta</i> , 2020, 500, 120-127.	0.5	13
11	Diurnal Variation of Urinary Fabry Disease Biomarkers during Enzyme Replacement Therapy Cycles. <i>International Journal of Molecular Sciences</i> , 2020, 21, 6114.	1.8	3
12	Assessing the role of glycosphingolipids in the phenotype severity of Fabry disease mouse model. <i>Journal of Lipid Research</i> , 2020, 61, 1410-1423.	2.0	7
13	Identification of a Reliable Biomarker Profile for the Diagnosis of Gaucher Disease Type 1 Patients Using a Mass Spectrometry-Based Metabolomic Approach. <i>International Journal of Molecular Sciences</i> , 2020, 21, 7869.	1.8	11
14	Effects of Orally Delivered Alpha-Galactosidase A on Gastrointestinal Symptoms in Patients With Fabry Disease. <i>Gastroenterology</i> , 2020, 159, 1602-1604.	0.6	11
15	Therapeutic challenges in two adolescent male patients with Fabry disease and high antibody titres. <i>Molecular Genetics and Metabolism Reports</i> , 2020, 24, 100618.	0.4	2
16	Mass Spectrometry Evaluation of Biomarkers in the Vitreous Fluid in Gaucher Disease Type 3 with Disease Progression Despite Long-Term Treatment. <i>Diagnostics</i> , 2020, 10, 69.	1.3	0
17	Mass spectrometry analysis of urinary methylmalonic acid to screen for metabolic vitamin B deficiency in older adults. <i>Bioanalysis</i> , 2020, 12, 693-705.	0.6	8
18	Distribution of heparan sulfate and dermatan sulfate in mucopolysaccharidosis type II mouse tissues pre- and post-enzyme-replacement therapy determined by UPLC-MS/MS. <i>Bioanalysis</i> , 2019, 11, 727-740.	0.6	6

#	ARTICLE	IF	CITATIONS
19	Tandem mass spectrometry analysis of urinary podocalyxin and podocin in the investigation of podocyturia in women with preeclampsia and Fabry disease patients. <i>Clinica Chimica Acta</i> , 2019, 495, 67-75.	0.5	17
20	Mutation-specific Fabry disease patient-derived cell model to evaluate the amenability to chaperone therapy. <i>Journal of Medical Genetics</i> , 2019, 56, 548-556.	1.5	43
21	Neonatal Mass Urine Screening Approach for Early Detection of Mucopolysaccharidoses by UPLC-MS/MS. <i>Diagnostics</i> , 2019, 9, 195.	1.3	8
22	Globotriaosylsphingosine (Lyso-Gb ₃) as a biomarker for cardiac variant (N215S) Fabry disease. <i>Journal of Inherited Metabolic Disease</i> , 2018, 41, 239-247.	1.7	25
23	Analysis of globotriaosylceramide (Gb ₃) isoforms/analogs in unfractionated leukocytes, B lymphocytes and monocytes from Fabry patients using ultra-high performance liquid chromatography/tandem mass spectrometry. <i>Analytica Chimica Acta</i> , 2018, 1015, 35-49.	2.6	9
24	The lysosomal enzyme alpha-Galactosidase A is deficient in Parkinson's disease brain in association with the pathologic accumulation of alpha-synuclein. <i>Neurobiology of Disease</i> , 2018, 110, 68-81.	2.1	38
25	Biomarkers associated with clinical manifestations in Fabry disease patients with a late-onset cardiac variant mutation. <i>Clinica Chimica Acta</i> , 2017, 466, 185-193.	0.5	44
26	High-Risk Screening for Fabry Disease: Analysis by Tandem Mass Spectrometry of Globotriaosylceramide (Gb ₃) in Urine Collected on Filter Paper. <i>Current Protocols in Human Genetics</i> , 2017, 93, 17.26.1-17.26.12.	3.5	10
27	Lentivector Iterations and Pre-Clinical Scale-Up/Toxicity Testing: Targeting Mobilized CD34 + Cells for Correction of Fabry Disease. <i>Molecular Therapy - Methods and Clinical Development</i> , 2017, 5, 241-258.	1.8	36
28	Separation and Analysis of Lactosylceramide, Galabiosylceramide, and Globotriaosylceramide by LC-MS/MS in Urine of Fabry Disease Patients. <i>Analytical Chemistry</i> , 2017, 89, 13382-13390.	3.2	31
29	Glycosphingolipid storage in Fabry mice extends beyond globotriaosylceramide and is affected by ABCB1 depletion. <i>Future Science OA</i> , 2016, 2, FSO147.	0.9	6
30	Evaluation of urinary keratan sulfate disaccharides in MPS IVA patients using UPLC-MS/MS. <i>Bioanalysis</i> , 2016, 8, 179-191.	0.6	17
31	Tandem Mass Spectrometry Quantitation of Lyso-Gb ₃ and Six Related Analogs in Plasma for Fabry Disease Patients. <i>Current Protocols in Human Genetics</i> , 2016, 90, 17.23.1-17.23.9.	3.5	14
32	Maternal inhaled fluticasone propionate intake during pregnancy is detected in neonatal cord blood. <i>Bioanalysis</i> , 2016, 8, 1441-1450.	0.6	2
33	Fabry Disease Biomarkers: Analysis of Urinary Lyso-Gb ₃ and Seven Related Analogs Using Tandem Mass Spectrometry. <i>Current Protocols in Human Genetics</i> , 2016, 90, 17.22.1-17.22.12.	3.5	8
34	Relative distribution of Gb ₃ isoforms/analogs in NOD/SCID/Fabry mice tissues determined by tandem mass spectrometry. <i>Bioanalysis</i> , 2016, 8, 1793-1807.	0.6	14
35	High-Risk Screening of Fabry Disease: Analysis of Fifteen Urinary Methylated and Non-Methylated Gb ₃ Isoforms Using Tandem Mass Spectrometry. <i>Current Protocols in Human Genetics</i> , 2016, 91, 17.24.1-17.24.11.	3.5	1
36	Diagnosis of late-onset Pompe disease and other muscle disorders by next-generation sequencing. <i>Orphanet Journal of Rare Diseases</i> , 2016, 11, 8.	1.2	42

#	ARTICLE	IF	CITATIONS
37	Tandem Mass Spectrometry Multiplex Analysis of Glucosylceramide and Galactosylceramide Isoforms in Brain Tissues at Different Stages of Parkinson Disease. <i>Analytical Chemistry</i> , 2016, 88, 1856-1863.	3.2	68
38	Tandem mass spectrometry multiplex analysis of methylated and non-methylated urinary Gb3 isoforms in Fabry disease patients. <i>Clinica Chimica Acta</i> , 2016, 452, 191-198.	0.5	23
39	Metabolomic Discovery of Novel Urinary Galabiosylceramide Analogs as Fabry Disease Biomarkers. <i>Journal of the American Society for Mass Spectrometry</i> , 2015, 26, 499-510.	1.2	42
40	Variations in the GLA gene correlate with globotriaosylceramide and globotriaosylsphingosine analog levels in urine and plasma. <i>Clinica Chimica Acta</i> , 2015, 447, 96-104.	0.5	22
41	Urinary biomarker investigation in children with Fabry disease using tandem mass spectrometry. <i>Clinica Chimica Acta</i> , 2015, 438, 195-204.	0.5	62
42	Multiplex Tandem Mass Spectrometry Analysis of Novel Plasma Lyso-Gb ₃ -Related Analogues in Fabry Disease. <i>Analytical Chemistry</i> , 2014, 86, 3476-3483.	3.2	71
43	A Metabolomic Study To Identify New Globotriaosylceramide-Related Biomarkers in the Plasma of Fabry Disease Patients. <i>Analytical Chemistry</i> , 2013, 85, 9039-9048.	3.2	56
44	Multiplex Analysis of Novel Urinary Lyso-Gb ₃ -Related Biomarkers for Fabry Disease by Tandem Mass Spectrometry. <i>Analytical Chemistry</i> , 2013, 85, 1743-1752.	3.2	72
45	LC-MS/MS analysis of plasma lyso-Gb ₃ in Fabry disease. <i>Clinica Chimica Acta</i> , 2012, 414, 273-280.	0.5	53
46	Urinary Globotriaosylsphingosine-Related Biomarkers for Fabry Disease Targeted by Metabolomics. <i>Analytical Chemistry</i> , 2012, 84, 2745-2753.	3.2	82